RecruitingPhase 3NCT04804553
Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
Studying Psoriasis-related juvenile idiopathic arthritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amgen
- Principal Investigator
- MDAmgen
- Intervention
- Apremilast(drug)
- Enrollment
- 60 enrolled
- Eligibility
- 5-17 years · All sexes
- Timeline
- 2022 – 2028
Study locations (30)
- Landeskrankenhaus Bregenz, Bregenz, Austria
- Universitair Ziekenhuis Gent, Ghent, Belgium
- Centre Hospitalier Regional de la Citadelle, Liège, Belgium
- Ziekenhuis Netwerk Antwerpen Jan Palfijn, Merksem, Belgium
- Hospices Civils de Lyon Hopital Femme Mere Enfant, Bron, France
- Hopital Jeanne de Flandre, Lille, France
- Charite - Universitaetsmedizin Berlin, Campus Virchow, Berlin, Germany
- Universitaetsklinikum Dresden, Dresden, Germany
- An der Schoen Klinik Hamburg Eilbek, Hamburg, Germany
- Asklepios Kinderklinik Sankt Augustin GmbH, Sankt Augustin, Germany
- Agia Sofia Children Hospital, Athens, Greece
- Attikon University General Hospital, Athens, Greece
- General Hospital of Thessaloniki Ippokrateio, Thessaloniki, Greece
- Ospedale Santissima Annunziata, Chieti, Italy
- IRCCS Istituto Giannina Gaslini, Genova, Italy
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04804553 on ClinicalTrials.govOther trials for Psoriasis-related juvenile idiopathic arthritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06751238Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).Novartis Pharmaceuticals
- RECRUITINGPHASE3NCT06869551A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic ArthritisBristol-Myers Squibb
- RECRUITINGPHASE3NCT06668181An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisUCB Biopharma SRL
- RECRUITINGPHASE3NCT06100744A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabAbbVie
- RECRUITINGPHASE3NCT05767047A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic ArthritisAmgen
- ACTIVE NOT RECRUITINGPHASE3NCT05083182A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic ArthritisJanssen Research & Development, LLC
- ACTIVE NOT RECRUITINGPHASE3NCT04527380A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic ArthritisEli Lilly and Company
See all trials for Psoriasis-related juvenile idiopathic arthritis →